PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

W58P0522C0008 — COVID-19 ANTIGEN OTC TEST KITS

COVID-19 ANTIGEN OTC TEST KITS is a federal NONE award for Department of Defense (DOD) held by ABBOTT RAPID DX NORTH AMERICA, LLC. Estimated value $1.3B ($1.3B obligated). Current period of performance ends Jun 30, 2022. Last award drew 20 bidders. Place of performance: ORLANDO, FL. Related solicitation W58P0522R0003.

$1.3B
Estimated Value
Jun 30, 2022
PoP End / Expires
20
Bidders (last award)
More in SCOUT — score this to your firm →See related expiring contracts →

Analysis

Public

ABBOTT RAPID DX NORTH AMERICA, LLC holds $42.8M across 9,132 federal awards, concentrated at Department of Defense (DOD). Competition previously drew 20 offers. Set-aside status: NONE. PoP ended Jun 30, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Contract facts

NONE
Contract numberW58P0522C0008
AgencyDepartment of Defense (DOD)
IncumbentABBOTT RAPID DX NORTH AMERICA, LLC
UEIP782RNU1NNK3
NAICS325413

No full NAICS 325413 intel page yet. Browse NAICS intelligence

PSC6515
Place of performanceORLANDO, FL
Related solicitationW58P0522R0003
PoP end (current)Jun 30, 2022
Obligated$1.3B

Recompete timing

Public
● Past PoP end (1502 days ago)

Current PoP ended Jun 30, 2022 (1502 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Track recompete timing in SCOUT →

Incumbent footprint

Public record

ABBOTT RAPID DX NORTH AMERICA, LLC — $42.8M obligated across 9,132 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($42.8M) · all agencies · Top 2 shown (11%); remaining ~89% is other agencies.
Department of Defense (DOD)$4.4M · 10%
Department of State (DOS)$368K · 1%
Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Score this to your firm — $90 Pilot →

Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. 90 days · $90 · no annual contract · cancel anytime

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open ABBOTT RAPID DX NORTH AMERICA, LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract W58P0522C0008?

W58P0522C0008 (COVID-19 ANTIGEN OTC TEST KITS) is a Department of Defense (DOD) award with an estimated value of $1.3B, currently held by ABBOTT RAPID DX NORTH AMERICA, LLC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on W58P0522C0008?

ABBOTT RAPID DX NORTH AMERICA, LLC is the incumbent with $42.8M across 9132 related awards in SCOUT’s public footprint. The current period of performance ends Jun 30, 2022.

When does W58P0522C0008 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 30, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W58P0522C0008